IGC Pharma, Inc. NYSE American: IGC

Our scientists published a new review in Academia Drug Development and Pharmacotherapy on how the endocannabinoid system regulates inflammation in the Alzheimer’s brain, drawing on research from 2002 to 2026. $IGC academia.edu/3071-2521/2/4/1…

Evelyn Gutiérrez, our Associate Director of Research and Clinical Trials, on what drives her work in Alzheimer’s research. $IGC

November is National Alzheimer’s Disease Awareness Month and National Family Caregivers Month. Some of the hardest moments in Alzheimer’s come from symptoms beyond memory loss, like agitation. Agitation is the focus of CALMA, our Phase 2 trial of investigational IGC-AD1. $IGC igcpharma.com/igc-ad1-phase-…

Two ways we’re applying AI to Alzheimer’s: • MINT-AD, our patent-pending platform for Alzheimer’s risk insights, moving toward real-world use through PRISM • aha™, which harmonizes research data from different studies igcpharma.com

In a double-blind trial, neither participants nor their doctors know who is receiving the investigational drug and who is receiving placebo. It keeps expectations from shaping the results, which is why it’s the standard design for testing a new treatment.

Clinical agitation in Alzheimer’s isn’t a bad mood. It’s a symptom of the disease, and one of the hardest for families to manage. What it is, in 90 seconds: #AlzheimersResearch

Combining Alzheimer’s data from different studies takes researchers hours of manual work. aha™, our AI tool, cut one representative workflow from 28 hours to 2.5, with a person reviewing the results. It will be deployed on the Alzheimer’s Disease Data Initiative’s (@AlzData) research platform.

Behavioral and psychological symptoms add another layer of complexity to Alzheimer's disease. Their variability is one reason researchers continue to study how they develop and change over time. #AlzheimersResearch

PRISM is the latest step in IGC Pharma's Alzheimer's AI strategy Designed to bring the patent-pending MINT-AD platform closer to real-world healthcare applications, PRISM is intended to move AI-generated Alzheimer's risk insights into action Read more: igcpharma.com/igc-pharma-unv… #AlzheimersResearch

Sleep is essential for overall brain health, and researchers continue to explore how changes in sleep may be connected to Alzheimer's disease What has research revealed so far? Read more: igcpharma.com/how-sleep-supp… #AlzheimersResearch #SleepResearch #BrainHealth

With target enrollment complete, IGC Pharma’s Phase 2 CALMA Alzheimer’s trial has officially transitioned from recruitment to the final stage ahead of topline results Topline results are expected in Q4 2026 Read more: igcpharma.com/igc-pharma-com… #AlzheimersResearch #IGCPharma

More than 55 million people worldwide are living with Alzheimer's disease This World Alzheimer's Day, we recognize everyone affected by the disease and reaffirm our commitment to advancing Alzheimer's research #WorldAlzheimersDay

Blood biomarkers are becoming an important area of Alzheimer's research The most widely studied include: • p-tau • Amyloid-beta (Aβ) • Neurofilament light (NfL) Each provides researchers with different insights into the biology of Alzheimer's disease #AlzheimersResearch

Women represent a disproportionate share of people living with Alzheimer's disease Researchers continue to investigate how factors such as longevity, hormonal changes, genetics, and brain biology may contribute to this disparity #AlzheimersDisease #WomensHealth

Advancing Alzheimer's research requires more than a single area of expertise By bringing together diverse scientific disciplines, researchers can deepen our understanding of the disease and help drive future discoveries #AlzheimersResearch #Neuroscience